DBV Technologies S.A. (DBVT) Given Buy Rating at HC Wainwright
DBV Technologies S.A. (NASDAQ:DBVT)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Monday. They currently have a $50.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 76.55% from the company’s current price.
A number of other brokerages have also recently commented on DBVT. Zacks Investment Research cut DBV Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 29th. Jefferies Group LLC reiterated a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. ValuEngine upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Leerink Swann increased their target price on DBV Technologies from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Friday, August 25th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DBV Technologies in a report on Monday, July 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $51.63.
Shares of DBV Technologies (NASDAQ DBVT) traded down 41.09% during mid-day trading on Monday, hitting $28.32. The stock had a trading volume of 13,148,037 shares. The company’s market cap is $1.30 billion. The stock has a 50 day moving average price of $44.94 and a 200-day moving average price of $39.47. DBV Technologies has a 52-week low of $22.33 and a 52-week high of $50.57.
TRADEMARK VIOLATION NOTICE: “DBV Technologies S.A. (DBVT) Given Buy Rating at HC Wainwright” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/23/dbv-technologies-s-a-dbvt-given-buy-rating-at-hc-wainwright.html.
A number of large investors have recently made changes to their positions in the business. Sabby Management LLC acquired a new stake in DBV Technologies during the 2nd quarter valued at $1,339,000. Dynamic Technology Lab Private Ltd acquired a new stake in DBV Technologies during the 2nd quarter valued at $222,000. Janus Henderson Group PLC acquired a new stake in DBV Technologies during the 2nd quarter valued at $90,724,000. Sectoral Asset Management Inc grew its holdings in DBV Technologies by 34.2% during the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock valued at $6,398,000 after buying an additional 45,653 shares during the last quarter. Finally, Airain ltd acquired a new stake in DBV Technologies during the 2nd quarter valued at $333,000. Hedge funds and other institutional investors own 45.52% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.